Imagine Health, Inc.

imaginehealth.com

Imagine Health is an exclusively high quality health plan and provider network delivering better care, a premium experience, and lower costs to its members and their employers. With a network shaped by the industry’s best data-driven methods for identifying the top tier of doctors, hospitals, and specialists, patients see the only the most effective providers. Personalized concierge assistance affords a low-stress experience for members that ensures their families get the right care and understand every step in straightforward terms.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MedTech

SEEGENE DEVELOPS WORLD'S FIRST COVID-19 DIAGNOSTIC VARIANT TEST CAPABLE OF IDENTIFYING MULTIPLE MUTANT VARIATIONS

Seegene | February 01, 2021

news image

South Korea's biotechnology firm Seegene (KQ096530) said Monday it built up the world's first COVID-19 diagnostic variation test, fit for screening COVID-19 and recognizing various mutant variations in a single reaction. Seegene's new variation test, the 'Allplex™ SARS-CoV-2 Variants I Assay,' can detect and separate virus variations, including those discovered to be more contagious and fatal. The new variation test identifies COVID-1...

Read More

SAMSUNG BIOLOGICS, VIR BIOTECHNOLOGY TEAM UP TO FIGHT COVID-19

BioSpectrum Asia | April 13, 2020

news image

South Korea based Samsung Biologics and US based Vir Biotechnology, Inc. have announced a manufacturing agreement under which Samsung Biologics will perform large scale manufacturing services Vir's SARS-CoV-2 monoclonal antibody (mAb) program. Vir's lead SRS-CoV-2 mAb development candidates, VIR-7831 and VIR-7832, have demonstrated high affinity for the SARS-CoV-2 spike protein and are highly potent in neutralizing SARS-CoV-2 in live-virus cellular assays. Vir plans to proceed directly i...

Read More

GREATER CFDNA RECOVERY MAY HELP ACCELERATE DEVELOPMENT OF CANCER LIQUID BIOPSY APPLICATIONS

PHASE Scientific | June 22, 2020

news image

PHASE Scientific, a high-growth biotechnology company that develops innovative sample preparation technologies, announced new findings at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II. The study presented by MD Anderson Cancer Center evaluates the efficacy of PHASE Scientific's liquid phase DNA isolation method (PHASIFY™) in improving cancer liquid biopsy sensitivity.Early-stage cancer diagnostics and cancer screening applications are limited ...

Read More

Industrial Impact

EYEBIO RAISES $65M IN SERIES A FUNDING TO DEVELOP NEW GENERATION OF EYE DISEASE THERAPIES

Eyebiotech Limited | February 23, 2022

news image

Eyebiotech Limited a privately held ophthalmology biotechnology company working to deliver a new generation of therapies for eye diseases, today announced the completion of a successful $65 million Series A funding round. SV Health Investors led the round, alongside Samsara BioCapital and Jeito Capital, with additional financial backing from MRL Ventures. The Series A brings together an international team of executives and investors with an extensive track record for developing ground-breaking o...

Read More
news image

MedTech

SEEGENE DEVELOPS WORLD'S FIRST COVID-19 DIAGNOSTIC VARIANT TEST CAPABLE OF IDENTIFYING MULTIPLE MUTANT VARIATIONS

Seegene | February 01, 2021

South Korea's biotechnology firm Seegene (KQ096530) said Monday it built up the world's first COVID-19 diagnostic variation test, fit for screening COVID-19 and recognizing various mutant variations in a single reaction. Seegene's new variation test, the 'Allplex™ SARS-CoV-2 Variants I Assay,' can detect and separate virus variations, including those discovered to be more contagious and fatal. The new variation test identifies COVID-1...

Read More
news image

SAMSUNG BIOLOGICS, VIR BIOTECHNOLOGY TEAM UP TO FIGHT COVID-19

BioSpectrum Asia | April 13, 2020

South Korea based Samsung Biologics and US based Vir Biotechnology, Inc. have announced a manufacturing agreement under which Samsung Biologics will perform large scale manufacturing services Vir's SARS-CoV-2 monoclonal antibody (mAb) program. Vir's lead SRS-CoV-2 mAb development candidates, VIR-7831 and VIR-7832, have demonstrated high affinity for the SARS-CoV-2 spike protein and are highly potent in neutralizing SARS-CoV-2 in live-virus cellular assays. Vir plans to proceed directly i...

Read More
news image

GREATER CFDNA RECOVERY MAY HELP ACCELERATE DEVELOPMENT OF CANCER LIQUID BIOPSY APPLICATIONS

PHASE Scientific | June 22, 2020

PHASE Scientific, a high-growth biotechnology company that develops innovative sample preparation technologies, announced new findings at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II. The study presented by MD Anderson Cancer Center evaluates the efficacy of PHASE Scientific's liquid phase DNA isolation method (PHASIFY™) in improving cancer liquid biopsy sensitivity.Early-stage cancer diagnostics and cancer screening applications are limited ...

Read More
news image

Industrial Impact

EYEBIO RAISES $65M IN SERIES A FUNDING TO DEVELOP NEW GENERATION OF EYE DISEASE THERAPIES

Eyebiotech Limited | February 23, 2022

Eyebiotech Limited a privately held ophthalmology biotechnology company working to deliver a new generation of therapies for eye diseases, today announced the completion of a successful $65 million Series A funding round. SV Health Investors led the round, alongside Samsara BioCapital and Jeito Capital, with additional financial backing from MRL Ventures. The Series A brings together an international team of executives and investors with an extensive track record for developing ground-breaking o...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us